期刊文献+

老年高血压并存心房颤动患者左心房内径和血栓前状态研究 被引量:17

Study of left fibrillation Geriatrics, atrial diameters and prothrombotic state in senile patients with hypertension and atrial
原文传递
导出
摘要 目的探讨老年高血压并存心房颤动(房颤)患者左心房内径(LAD)的变化及其与血栓前状态各指标的相关性。方法高血压患者105例,其中65例并存房颤(房颤组),40例无房颤(非房颤组),30例健康体检无高血压和房颤为对照组。用M型心脏超声测定LAD,同时检测其纤维蛋白原(Fg)、D-二聚体(D-Dimer)、血浆假性血友病因子(vwF)及红细胞压积(HCT),并进行比较。再将房颤患者分为阵发性房颤组和持续性房颤组,比较其LAD、Fg、D-Dimer、vwF、HCT。然后以LAD为因变量,Fg、D-Dimer、vwF、HCT为自变量,进行直线相关分析。结果房颤组与对照组和非房颤组比较,LAD为(43.56±6.72)mm与(31.63±4.32)mm和(36.28±5.83)mm(均P〈0.05),Fg为(4.24±0.59)g/L与(2.80±0.46)g/L和(3.09士0.49)g/L(均P〈0.05),D-Dimer为(0.43±0.13)mg/L与(0.18±0.08)mg/L和(0.28±0.10)mg/L(均P〈0.05);房颤组vwF、HCT分别为(290.44±29.02)%、0.46±0.07,与对照组(84.15士20.26)%、0.34±0.03比较,差异有统计学意义(均P〈0.05)。非房颤组与对照组比较,LAD、D-Dimer差异有统计学意义(P〈0.05)。持续房颤组与阵发房颤组比较,LAD、Fg、D-Dimer、vwF、HCT差异有统计学意义(均P〈0.05),LAD与Fg(r=0.683)、D-Dimer(r=0.735)、vwF(r=0.763)、HCT(r=0.759)呈正相关(均P〈0.01)。结论LAD增大为房颤发生的危险因素,房颤患者存在血栓前状态,且LAD越大,血栓风险越大。 Objective To explore the relationship between left atrial diameters (LAD) and prothrombotic state in senile patients with hypertension (HT) and atrial fibrillation (AF). Methods Totally 105 patients with essential hypertension were divided into 65 patients with atrial fibrillation and 40 cases without atrial fibrillation, and then patients with atrial fibrillation were subgrouped into paroxysmal and persistent atrial fibrillation groups. 30 healthy people without hypertension and atrial fibrillation were used as control group. LAD was determined by M type ultrasound cardiogram. Fibrinogen (Fg), D-Dimer(D-Dimer), yon willebrand (vwF) and haematocrit (HCT) were also measured as prothrombotic state and compared among the groups. Results In groups of HT with AF versus HT without AF versus control, LAD[(43.56 ± 6.72) mm vs. (36.28 ± 5.83) mm vs. (31.63±4.32)mm3, Fg[(4.24±0.59)g/L vs. (3.09 ±0.49)g/L vs. (2.80 ±0.46)g/L3, D-Dimer ((0.43±0.13)mg/L vs. (0.28±0.10)mg/L vs. (0.18±0.08)mg/L3,vwF((290.44±29.02)% vs. (101.32±21.36)% vs. (84.15±20.26)%], HCT[(0.46±0.07)vs. (0.37±0.05)vs. (0.34±0.03)3 were significantly higher in HT patients with atrial fibrillation than those without atrial fibrillation and control ( all P〈 0.05), and there were differences in LAD and D-Dimer (P〈0.05), but not in Fg, vwF and HCT (all P〉0.05) between patients without atrial fibrillation and control. LAD[(46.75± 7.32)ram vs. (40.82±6.21)mm], Fg ((4. 68±0. 65)g/L vs. (3.85±0.53)g/L3, D-Dimer [(0.48± 0.16)mg/L vs. (0.40±0.12)mg/L3, vwF [(384.96±29.75)] vs. (209.43±28.63)%3 and HCT [(0.49±0.08)vs. (0.43±0.06)3 in persistent atrial fibrillation group were increased than those in paroxysmal atrial fibrillation group (P〈0.05). Fg (r=0.683), D-Dimer(r=0.735), vwF(r= 0. 763) and HCT(r=0. 759)were correlated with LAD (all P〈0.01). Conclusions Increased LAD might be one of the elevated risks of atrial fibrillation and a higher prothrombotic state is increasing with larger LAD in senile hypertension.
出处 《中华老年医学杂志》 CAS CSCD 北大核心 2012年第3期182-184,共3页 Chinese Journal of Geriatrics
关键词 心房颤动 心房功能 血栓形成 Atrial fibrillation Atrial function, left Thrombosis
  • 相关文献

参考文献11

  • 1ACC/AHA/ESC. 2006 Guidelines for the management of patients with atrial fibrillation. JACC, 2006, 48:149-246.
  • 2Conway DS, Heeringa J, van der Kuip DA, et al. Atrial fibrillation and the prothrombotic state in the elderly: the Rotterdam Study. Stroke, 2003, 34 : 413- 417.
  • 3Ausma J,Dispersyn GD,Duimel H, et al. Changes in ultrastructural calcium distribut in goat atria during atrial fibrillation. J Mol Cell Cardiol, 2000, 32:355- 364.
  • 4Healey JS, Connolly SJ. Atrial fibrillation: hypertension as a causative agent, risk factor for complication,and potential therapeutic target. Am J Cardiol, 2003, 91:9-14.
  • 5VaziriSM, Larson MG, Benjamin EJ, et al. Echocardiographic predictor in nonrheumatic Atrial fibrillation ~ the Framingham Heart Study. Circulation, 1994,89 :724-730.
  • 6黄瑛,刘志华.血栓前状态与心房颤动[J].继续医学教育,2005,19(6):54-57. 被引量:8
  • 7Mondillo S,Sabatini L, Agricola E,et al. Correlati on between left atrial size, prothrombotic state and markers of endothelialdys function in patients with lone chronic nonrheumatic atrial fibrillation. Int J Cardiol, 2000, 75: 227-232.
  • 8王华,杨杰孚,包承鑫,胡云建,钟优,张瑞生,曾学寨,李宏义,刘德平.心房颤动患者高凝状态研究[J].临床荟萃,2006,21(7):461-464. 被引量:12
  • 9阴大伟,李小鹰.预防心房颤动患者脑卒中的药物治疗新进展[J].中华老年医学杂志,2011,30(6):523-526. 被引量:4
  • 10郭继鸿.心房颤动的抗凝治疗2011[J].中国心血管杂志,2011,16(2):83-86. 被引量:9

二级参考文献58

  • 1王鸿利,宋善俊.分子标志物在诊断血栓前状态的意义[J].国外医学(输血及血液学分册),1995,18(2):68-72. 被引量:67
  • 2Furberg CD,Psaty BM,Manolio TA,et al.Prevalence of atrial fibrillation in elderly subjects (the Cardiovascular Health Study).Am J Cardiol,1994,74:236-241.
  • 3Go AS,Hylek EM,Phillips KA,et al.Prevalence of diagnosed atrial fibrillation in adults:national implications for rhythm management and stroke prevention:the AnTicoagulation and Risk Factors in Atrial Fibrillation (ATRIA) study.JAMA,2001,285:2370-2375.
  • 4Gage BF,van Walraven C,Pearce L,et al.Selecting patients with atrial fibrillation for anticoagulation:stroke risk stratification in patients taking aspirin.CIrculation,2004,110:2287-2292.
  • 5Hart RG,Pearce LA,Aguilar MI.Meta-analysis:antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation.Ann Intern Med,2007,146:857-867.
  • 6ACTIVE Investigators,Connolly SJ,Pogue J,et al.Effect of clopidogrel added to aspirin in patients with atrial fibrillation.N Engl J Med,2009,360:2066-2078.
  • 7ACTIVE Writing Group of the ACTIVE Investigators,Connolly S,Pogue J,et al.Clopidogrel plus aspirin versus oral anticoagulation for atrial fibrillation in the Atrial Fibrillation Clopidogrel Trial with Lrbesartan for Prevention of Vascular Events (ACTIVE-W):a randomized controlled trial.Lancet,2006,367:1903-1912.
  • 8Nieuwlatt R,CapucCI A,Lip GYH,et al.Antithrombotic treatment in real-life atrial fibrillation patients:a report from the Euro Heart Survey on Atrial Fibrillation.Eur Heart J,2006,27:3018-3026.
  • 9Birman-Deych E,Radford MJ,Nilasena DS,et al.Use and effectiveness of warfarin in medicare benefiCIaries with atrial fibrillation.Stroke,2006,37:1070-1074.
  • 10Bungard TJ,Ghali WA,Teo KK,et al.Why do patients with atrial fibrillation not receive warfarin? Arch Intern Med,2000,160:41-46.

共引文献28

同被引文献167

引证文献17

二级引证文献74

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部